Atea Pharmaceuticals Inc. (NASDAQ:AVIR) price closed lower on Monday, September 13, dropping -2.52% below its previous close.
A look at the daily price movement shows that the last close reads $28.60, with intraday deals fluctuated between $27.66 and $29.00. The company’s P/E ratio in the trailing 12-month period read 70.58. Taking into account the 52-week price action we note that the stock hit a 52-week high of $94.17 and 52-week low of $18.72. The stock subtracted -10.38% on its value in the past month.
Atea Pharmaceuticals Inc., which has a market valuation of $2.31 billion, is expected to release its quarterly earnings report Aug 12, 2021. Analysts tracking AVIR have forecast the quarterly EPS to shrink by -0.17 per share this quarter, while the same analysts predict the annual EPS to hit $0.58 for the year 2021 and up to $14.3 for 2022. In this case, analysts estimate an annual EPS growth of 213.70% for the year and 2,365.50% for the next year.
Staying with the analyst view, there is a consensus estimate of $287.73 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow 491.60% above that which the company brought in 2021.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give AVIR a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 4 analysts have assigned AVIR a recommendation rating as follows: 0 rate it as a Hold; 4 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Atea Pharmaceuticals Inc. (AVIR) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that AVIR’s price is at present -4.64% off the SMA20 and 2.95% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 46.46, with weekly volatility standing at 5.70%. The indicator jumps to 6.08% when calculated based on the past 30 days. Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 1.85. Considering analysts have assigned the stock a price target range of $37.00-$60.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $51.00. Based on this estimate, we see that current price is roughly -32.71% off the estimated low and -115.21% off the forecast high. Investors will no doubt be excited to see the share price fall to $56.00, which is the median consensus price, and at that level AVIR would be -100.86% from current price.
An analysis of the Atea Pharmaceuticals Inc. (NASDAQ:AVIR) stock in terms of its daily trading volume indicates that the 3-month average is 1.39 million.
Current records show that the company has 82.74M in outstanding shares. The insiders’ percentage holdings are 18.48% of outstanding shares while the percentage share held by institutions stands at 71.20%. But the -33.27% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.